Short answer
TANDEM DIABETES CARE INC (TNDM) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $249M (up 2.2% year over year) with net income of −$21M.
Q3 2025 key financials · XBRL
- Revenue
- $249M
- +2.2% YoY · +3.6% QoQ
- Net income
- −$21M
- +9.0% YoY · +59.6% QoQ
- Operating margin
- -9.2%
- Gross margin
- 53.9%
- EPS (diluted)
- −$0.30
- +14.3% YoY · +61.0% QoQ
Source: XBRL data from the TANDEM DIABETES CARE INC (TNDM) Q3 2025 10-Q on SEC EDGAR. USD.
TANDEM DIABETES CARE INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: CMS proposed competitive bidding process and payment changes for insulin pumps (June 30, 2025) could reduce reimbursement and impact revenue recognition
- Updated competitive risk: Increased adoption of GLP-1 drugs since 2023 negatively impacts insulin therapy market demand
- Regulatory risk: CMS and other third-party payors may modify diabetes product coverage and reimbursement, with contracts subject to audit, modification, or termination
- Operational risk: Dependence on independent U.S. distributors who may prioritize competitor products, risking sales declines if distributors reduce support
- Financial risk: Accumulated deficit of $1.3 billion as of September 30, 2025, with continued expenses rising faster than sales, risking ongoing operating losses
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other TANDEM DIABETES CARE INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.